PATENT COOPERATION TREATY

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

SCHWANDER, Kuno, Josef Roche Vitamins Ltd. Wurmisweg 576 CH-4303 Kaiseraugst SUISSE

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(PCT Rule 71.1)

Date of mailing

(day/month/year)

04.03.2005

Applicant's or agent's file reference

Case 21722

IMPORTANT NOTIFICATION

International application No. PCT/EP2004/003110

International filing date (day/month/year) 24.03.2004

Priority date (day/month/year)

03.04.2003

Applicant

DSM IP ASSETS B.V.

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:



European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 **Authorized Officer**

Ruiz Fernandez, J

Tel. +49 89 2399-7960



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference Case 21722	FOR FURTHER ACTIO	N See F	orm PCT/IPEA/416	
International application No. International filing date PCT/EP2004/003110 24.03.2004		•	ority date <i>(day/month/year)</i> 04.2003	
International Patent Classification (IPC) or A23L1/302, A23L1/303, A23L1/305		23J1/14, A61K8/64		
Applicant DSM IP ASSETS B.V.			:-	
 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 				
2. This REPORT consists of a total of 5 sheets, including this cover sheet.				
3. This report is also accompanied by ANNEXES, comprising:				
a. 🛮 sent to the applicant and to the International Bureau) a total of 2 sheets, as follows:				
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.				
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4. This report contains indications	relating to the following items:		•	
Box No. II Priority				
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			nd industrial applicability	
☐ Box No. IV Lack of unity of				
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
☐ Box No. VI Certain documents cited				
Box No. VII Certain defects in the international application				
Box No. VIII Certain observations on the international application				
Date of submission of the demand		e of completion of this report		
29.10.2004		04.03.2005		
Name and mailing address of the international		norized Officer	na Para	
preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d		eets, D	Total ON E	
Fax: +49 89 2399 - 4465		phone No. +49 89 2399-749	92	

JC12 Rec'd PCT/PTC 27 SEP 2005

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/003110

Ξ	Box No	o. I Basis of the report			
1.		gard to the language , this report is based on the international application in the language in which it wan nless otherwise indicated under this item.			
		is report is based on translations from the original language into the following language, iich is the language of a translation furnished for the purposes of:			
		international search (under Rules 12.3 and 23.1(b)) publication of the international application (under Rule 12.4) international preliminary examination (under Rules 55.2 and/or 55.3)			
2.	. With regard to the elements* of the international application, this report is based on (replacement sheets who have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):				
	Descrip	otion, Pages			
	1-5	as originally filed			
	Claims,	Numbers			
1-12		received on 04.02.2005 with letter of 02.02.2005			
	□ as	sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing			
3. [□ Th	The amendments have resulted in the cancellation of:			
		the description, pages			
		the claims, Nos.			
		the drawings, sheets/figs the sequence listing (specify):			
		any table(s) related to sequence listing (specify):			
4.	had not	is report has been established as if (some of) the amendments annexed to this report and listed below to been made, since they have been considered to go beyond the disclosure as filed, as indicated in the mental Box (Rule 70.2(c)).			
		the drawings, sheets/figs the sequence listing (specify):			
		any table(s) related to sequence listing (specify):			
	* If	item 4 applies, some or all of these sheets may be marked "superseded."			

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/003110

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-12

No:

Yes: Claims

Claims

1-12

Inventive step (IS)

No: Claims

Industrial applicability (IA)

Yes: Claims

1-12

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VI Certain documents cited

Certain published documents (Rule 70.10)
 and /or

2. Non-written disclosures (Rule 70.9)

see separate sheet

Re Item VI

Certain documents cited

Certain published documents

Application No Patent No

Publication date (day/month/year)

Filing date (day/month/year)

Priority date (valid claim) (day/month/year)

EP1405572

07.04.2004

04.10.2002

04.10.2002

&;

EP1405572 has a filing date prior to the priority date of the present application and could be relevant in some regional and/or national phases for the assessment of novelty.

Re Item V.

1. The following documents are referred to in this communication:

D1: DATABASE WPI Section Ch, Week 199515 Derwent Publications Ltd., London, GB; Class D13, AN 1995-113373; XP002287568 RU 2 017 434 C1 (GOLOVCHENKO V I) 15 August 1994 (1994-08-15)

D2: US 4 892 727 A (GROLLIER JEAN-FRANCOIS) 9 January 1990 (1990-01-09)

D3: WO 99/11143 A (BUTTIMER EILEEN TERESA; CANDY MICHAEL JOHN (GB); FITCHETT COLIN STANL) 11 March 1999 (1999-03-11)

D4: KING J ET AL: "FUNCTIONAL PROPERTIES OF LUPIN PROTEIN ISOLATES (LUPINUS ALBUS CV MULTOLUPA)" JOURNAL OF FOOD SCIENCE, INSTITUTE OF FOOD TECHNOLOGISTS. CHICAGO, US, vol. 50, no. 1, 1985, pages 82-87, XP002068531, ISSN: 0022-1147

D5: EP 1 106 174 A (HOFFMANN LA ROCHE) 13 June 2001 (2001-06-13)

2 Novelty and Inventive Step (Articles 33(1), (2) and (3) PCT)

None of the cited prior art documents D1-D5 teaches or suggests using native cross-linked lupin protein to prepare formulations comprising fat-soluble active ingredients. The formulations according to claims on file exhibit increased stability.

Thus, the subject-matter of independent claims 1, 9 and 10 is considered to be novel and inventive.

Claims 2-8, 11, 12 are dependent on claims 1 and 10 and as such also meet the

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2004/003110

requirements of the PCT with respect to novelty and inventive step.





10/551197 JC12 Rec'd PCT/PTC 27 SEP 2005

.

What is claimed is:

Case 21722

- 1. Stable powderous formulations comprising a fat-soluble active ingredient in a matrix of a native lupin protein composition wherein the protein is cross-linked.
- 2. Formulations according to claim 1, wherein the lupin protein composition is a lupin protein isolate having a protein content of more than 90 wt.-%.
- 3. Formulations according to claim 1, wherein the lupin protein composition is a lupin protein concentrate having a protein content of about 60-90 wt.-%.
- 4. Formulations according to claim 1, wherein the lupin protein composition is a lupin protein flour having a protein content of about 40-60 wt.-%.
- 5. Formulations according to claim 1, comprising mixtures of native lupin protein compositions as defined in claims 2-4.
 - 6. Formulations according to claim 1, wherein the fat-soluble active ingredient is vitamin A, D, E or K, or a carotenoid, or a polyunsaturated fatty acid, or esters thereof, or mixtures thereof.
- 7. Formulations according to claim 1, wherein the fat-soluble active ingredient is a plant or animal oil or fat, particularly sunflower oil, palm oil or corn oil.
 - 8. Formulations according to claim 1, comprising additionally a reducing sugar, particularly glucose, fructose, or xylose.
- 9. Food, beverages, animal feeds, cosmetics or drugs comprising a formulation according to any one of claims 1 8.
 - 10. Process for the preparation of formulations according to any one of claims 1 8, which comprises preparing an aqueous emulsion of the fat-soluble active ingredient and the native lupin protein composition, if desired, adding a reducing sugar, converting the









- 2 -

emulsion into a dry powder, and submitting the dry powder to cross-linking the protein by heat treatment or by treatment with a cross-linking enzyme.

- 11. A process according to claim 10 wherein a reducing sugar is added and the composition is submitted to crosslinking by heating.
- 12. A process according to claim 10 wherein the composition is submitted to crosslinking by treatment with a cross-linking enzyme, particularly transglutaminase.

